Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
- Status
- UNKNOWN
- Phase
- PHASE2
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
- Status
- UNKNOWN
- Phase
- PHASE3
Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.
- Status
- UNKNOWN
- Phase
- N/A
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
- Status
- COMPLETED
- Phase
- PHASE1
Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment
- Status
- WITHDRAWN
- Phase
- PHASE3
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Rituximab and RASi in Patients with IgAN
- Status
- COMPLETED
- Phase
- PHASE4
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Rituximab for Idiopathic Nephrotic Syndrome
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
- Status
- WITHDRAWN
- Phase
- PHASE2